{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:13:35Z","timestamp":1783685615236,"version":"3.55.0"},"reference-count":10,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    This commentary discusses the phase I study of fecal microbiota transplantation plus anti-programmed cell death protein 1 therapy in refractory microsatellite-stable gastric cancer. We suggest that this strategy should be treated as a pharmacomicrobiomic intervention rather than only as an immunotherapy combination. Evidence from fecal microbiota transplantation trials and microbiome immunotherapy studies indicates that antibiotics, proton pump inhibitors, corticosteroids and other microbiome-modifying exposures may affect donor strain engraftment, immune activation, response assessment and safety. In China and other Asian settings, where acid suppression,\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    history, perioperative antibiotic use and nutritional interventions are common, standardized concomitant medication reporting would make future studies more interpretable and transferable.\n                  <\/jats:p>","DOI":"10.1136\/jitc-2026-015908","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:20:39Z","timestamp":1783682439000},"page":"e015908","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Concomitant medication reporting should accompany fecal microbiota transplantation plus anti-PD-1 therapy in gastric cancer"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0645-5532","authenticated-orcid":false,"given":"Guofu","family":"Mao","sequence":"first","affiliation":[{"name":"Danyang People\u2019s Hospital and Affiliated Danyang Hospital of Nantong University, Danyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhen","family":"Lan","sequence":"additional","affiliation":[{"name":"Danyang People\u2019s Hospital and Affiliated Danyang Hospital of Nantong University, Danyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2026071004202295000_14.7.e015908.1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013823","article-title":"Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study","volume":"14","author":"Zhang","year":"2026","journal-title":"J Immunother Cancer"},{"key":"2026071004202295000_14.7.e015908.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02453-x"},{"key":"2026071004202295000_14.7.e015908.3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41591-025-04186-5","article-title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial","volume":"32","author":"Duttagupta","year":"2026","journal-title":"Nat Med"},{"key":"2026071004202295000_14.7.e015908.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.06.010"},{"key":"2026071004202295000_14.7.e015908.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01964-3"},{"key":"2026071004202295000_14.7.e015908.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"2026071004202295000_14.7.e015908.7","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-1014"},{"key":"2026071004202295000_14.7.e015908.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1070076","article-title":"Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis","volume":"14","author":"Lopes","year":"2023","journal-title":"Front Immunol"},{"key":"2026071004202295000_14.7.e015908.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2026071004202295000_14.7.e015908.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7015"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:20:40Z","timestamp":1783682440000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":10,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,10]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2026-015908"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015908","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}